Next Article in Journal
Protein Carbamylation: A Marker Reflecting Increased Age-Related Cell Oxidation
Next Article in Special Issue
Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor α in Human Acute Myeloid Leukemia Cell Lines
Previous Article in Journal
Fine Mapping and Candidate Gene Prediction for White Immature Fruit Skin in Cucumber (Cucumis sativus L.)
Previous Article in Special Issue
Ferritin Heavy Subunit Silencing Blocks the Erythroid Commitment of K562 Cells via miR-150 up-Regulation and GATA-1 Repression
Open AccessReview

The Making of Leukemia

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain
Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
Departamento de Fisiología y Farmacología, Universidad de Salamanca, Edificio Departamental, Campus M. de Unamuno s/n, 37007 Salamanca, Spain
Departamento de Cirugía, Universidad de Salamanca, 37007 Salamanca, Spain
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(5), 1494;
Received: 23 April 2018 / Revised: 8 May 2018 / Accepted: 14 May 2018 / Published: 17 May 2018
Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of leukemia. Studies on different types of hematopoietic tumors have shown that the contribution of oncogenes to leukemia is mainly mediated through the epigenetic reprogramming of the leukemia-initiating target cell. This driving of cancer by a malignant epigenetic stem cell rewiring is, however, not exclusive of the hematopoietic system, but rather represents a common tumoral mechanism that is also at work in epithelial tumors. Tumoral epigenetic reprogramming is therefore a new type of interaction between genes and their target cells, in which the action of the oncogene modifies the epigenome to prime leukemia development by establishing a new pathological tumoral cellular identity. This reprogramming may remain latent until it is triggered by either endogenous or environmental stimuli. This new view on the making of leukemia not only reveals a novel function for oncogenes, but also provides evidence for a previously unconsidered model of leukemogenesis, in which the programming of the leukemia cellular identity has already occurred at the level of stem cells, therefore showing a role for oncogenes in the timing of leukemia initiation. View Full-Text
Keywords: leukemia; oncogenes; reprogramming; stem cells; cancer therapy; leukemia stem cell; mouse model leukemia; oncogenes; reprogramming; stem cells; cancer therapy; leukemia stem cell; mouse model
Show Figures

Graphical abstract

MDPI and ACS Style

González-Herrero, I.; Rodríguez-Hernández, G.; Luengas-Martínez, A.; Isidro-Hernández, M.; Jiménez, R.; García-Cenador, M.B.; García-Criado, F.J.; Sánchez-García, I.; Vicente-Dueñas, C. The Making of Leukemia. Int. J. Mol. Sci. 2018, 19, 1494.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop